TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12693490

Group type: EXPERIMENTAL
Intervention: Overdrive biatrial pacing
Number of subjects: 776

Group type: EXPERIMENTAL
Intervention: Overdrive right atrial pacing
Number of subjects: 776

Group type: EXPERIMENTAL
Intervention: Fixed high-rate biatrial pacing
Number of subjects: 776

Group type: EXPERIMENTAL
Intervention: Fixed high-rate right atrial pacing
Number of subjects: 776

Group type: COMPARATOR
Intervention: Overdrive left atrial pacing
Number of subjects: 776
Study: 10376178

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 38
Study: 8721527

Group type: EXPERIMENTAL
Intervention: Acute allergen challenge (increasing doses every 15 min until symptoms occurred) in 9 patients.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Repeated low-dose allergen exposure (one small dose daily for 7 days) in 10 patients.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (4 patients challenged with diluent only).
Number of subjects: 19
Study: 1839557

Group type: EXPERIMENTAL
Intervention: Curettage with hydrocolloid occlusion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Curettage alone
Number of subjects: 30
Study: 6849206

Group type: EXPERIMENTAL
Intervention: Erythromycin gluceptate
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 98

Group type: COMPARATOR
Intervention: Overall
Number of subjects: 98
Study: 29096934

Group type: EXPERIMENTAL
Intervention: Motivational interviewing sessions at baseline, 3, 6, and 12 months, in addition to a brief physician recommendation to increase physical activity.
Number of subjects: 340

Group type: COMPARATOR
Intervention: Brief physician recommendation to increase physical activity to meet national guidelines.
Number of subjects: 340
Study: 28441975

Group type: EXPERIMENTAL
Intervention: Substance abuse treatment
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Condom use at last sex
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Physical assault in the past year
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Positive urine test for opiates or cocaine
Number of subjects: 641
Study: 26607061

Group type: EXPERIMENTAL
Intervention: Infant massage
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no massage)
Number of subjects: 56
Study: 22014414

Group type: EXPERIMENTAL
Intervention: Obese children
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Overweight children
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Obese and overweight children
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Obese group
Number of subjects: 91
Study: 21041707

Group type: EXPERIMENTAL
Intervention: Intervention (PSA screening)
Number of subjects: 73678

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 73678
Study: 18251647

Group type: EXPERIMENTAL
Intervention: Test group (removal of granulation tissue and soft microbial deposits by cleaning the root surface with a microbrush and saline solution, aiming at cementum preservation)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (scaling and root planing with removal of granulation tissue and root cementum)
Number of subjects: 30
Study: 16737375

Group type: EXPERIMENTAL
Intervention: Implicit disposition to approach goals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implicit disposition to avoid temptations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-control conflict magnitude
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Successful self-control
Number of subjects: 0
Study: 15298244

Group type: EXPERIMENTAL
Intervention: Oral balance gel
Number of subjects: 39

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 39
Study: 11151741

Group type: EXPERIMENTAL
Intervention: Felodipine ER 5 mg and Metoprolol CR/ZOC 50 mg (free combination)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Felodipine ER 5 mg and Metoprolol CR/ZOC 50 mg (fixed combination)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 9727214

Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment (ACT) model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blended ACT principles with the Rhinelander model
Number of subjects: 0
Study: 8360369

Group type: EXPERIMENTAL
Intervention: Relaxation treatment
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Relaxation+efficacy-enhancement treatment
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Relaxation-only condition
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard preparation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Oral premedication
Number of subjects: 70
Study: 3526884

Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 28161142

Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 38
Study: 26938752

Group type: EXPERIMENTAL
Intervention: Ulinastatin (UTL)
Number of subjects: 60
Study: 24622930

Group type: EXPERIMENTAL
Intervention: RVA pacing
Number of subjects: 164

Group type: COMPARATOR
Intervention: RVOT pacing
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 164
Study: 22017318

Group type: EXPERIMENTAL
Intervention: Therapeutic Massage (TM)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Passive Movement (PM)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (CTL)
Number of subjects: 44
Study: 19939873

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD) in dim light
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bright light after acute tryptophan depletion (ATD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dim light with balanced amino acid mixtures
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bright light with balanced amino acid mixtures
Number of subjects: 30
Study: 18416476

Group type: EXPERIMENTAL
Intervention: Omega-3 fish oil and soybean oil (LCT:fish oil = 5:1, Omegaven, Fresenius-Kabi)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Soybean oil (LCT; Intralipid, Fresenius-Kabi)
Number of subjects: 42
Study: 16030279

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (600 mg IV, 4 doses: 2 intraoperative and 2 postoperative)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (600 mg IV)
Number of subjects: 295
Study: 14622076

Group type: EXPERIMENTAL
Intervention: Experiential treatment for depression (16-20 sessions)
Number of subjects: 34
Study: 11079877

Group type: EXPERIMENTAL
Intervention: Concept Based Indexing using SNOMED‐RT
Number of subjects: 100

Group type: COMPARATOR
Intervention: Keyword Indexing
Number of subjects: 100
Study: 8964866

Group type: EXPERIMENTAL
Intervention: rhGH therapy (4 IU/m2.day, sc)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison group (10 subjects with NS)
Number of subjects: 30
Study: 1804652

Group type: EXPERIMENTAL
Intervention: Intranasal (IN) administration of midazolam 0.2 mg.kg‐1
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intravenous (IV) administration of midazolam 0.2 mg.kg‐1
Number of subjects: 12
Study: 6402201

Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.15 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Meptazinol (50 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Morphine (5 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pethidine (50 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intramuscular analgesic system
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous on demand systems
Number of subjects: 40
Study: 30858255

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: CRP training
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Communication training
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Both interventions combined
Number of subjects: 246
Study: 29959443

Group type: EXPERIMENTAL
Intervention: Multifaceted quality improvement intervention (2400 patients)
Number of subjects: 4800
Study: 27903289

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) (2 mA/day, three times per week for 3 weeks)
Number of subjects: 16
Study: 24777591

Group type: EXPERIMENTAL
Intervention: Therapeutic dose of NOMAC/E2 (2.5/1.5 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Supratherapeutic dose of NOMAC/E2 (12.5/7.5 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 100
Study: 22565934

Group type: EXPERIMENTAL
Intervention: 4 weeks of supervised endurance training
Number of subjects: 60
Study: 20384438

Group type: EXPERIMENTAL
Intervention: Desloratadine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18979976

Group type: EXPERIMENTAL
Intervention: Smoking intervention
Number of subjects: 719

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 719
Study: 16477959

Group type: COMPARATOR
Intervention: Eszopiclone 2 mg
Number of subjects: 231

Group type: COMPARATOR
Intervention: Eszopiclone 1 mg
Number of subjects: 231
Study: 12742761

Group type: EXPERIMENTAL
Intervention: Interview condition with several suggestive techniques
Number of subjects: 111

Group type: COMPARATOR
Intervention: Interview condition with only suggestive questions
Number of subjects: 111
Study: 10924966

Group type: EXPERIMENTAL
Intervention: Hyperfractionation at 1.2 Gy/fraction, twice daily, 5 days/week to 81.6 Gy/68 fractions/7 weeks
Number of subjects: 1113

Group type: EXPERIMENTAL
Intervention: Accelerated fractionation with concomitant boost at 1.8 Gy/fraction/day, 5 days/week and 1.5 Gy/fraction/day to a boost field for the last 12 treatment days to 72 Gy/42 fractions/6 weeks
Number of subjects: 1113

Group type: COMPARATOR
Intervention: Accelerated fractionation with split at 1.6 Gy/fraction, twice daily, 5 days/week to 67.2 Gy/42 fractions/6 weeks
Number of subjects: 1113

Group type: COMPARATOR
Intervention: Standard fractionation at 2 Gy/fraction/day, 5 days/week, to 70 Gy/35 fractions/7 weeks
Number of subjects: 1113
Study: 8972541

Group type: EXPERIMENTAL
Intervention: Nicotine (0.75 or 1.5 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 10
Study: 1462910

Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Rehydration
Number of subjects: 15
Study: 6738359

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Alcohol consumption (1 ounce)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Greater physical activity
Number of subjects: 164

Group type: COMPARATOR
Intervention: Smokers who exercise or consume alcohol
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Subjects who both exercise and consume alcohol
Number of subjects: 164
Study: 30501824

Group type: EXPERIMENTAL
Intervention: Dexamethasone administration to women before elective cesarean section (group 1)
Number of subjects: 535

Group type: COMPARATOR
Intervention: No steroid cover (group 2)
Number of subjects: 535
Study: 27608829

Group type: EXPERIMENTAL
Intervention: PilAm Go4Health Weight Loss Program (intervention group, n=22)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Wait list active control (control group, n=23)
Number of subjects: 45
Study: 24907062

Group type: EXPERIMENTAL
Intervention: DEX implant 0.7 mg
Number of subjects: 1048

Group type: EXPERIMENTAL
Intervention: DEX implant 0.35 mg
Number of subjects: 1048

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 1048
Study: 23072538

Group type: EXPERIMENTAL
Intervention: Juice consumption (400 mL of blended juice of açai, camu‐camu, and blackberries)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sugar solution (control)
Number of subjects: 12
Study: 19499321

Group type: EXPERIMENTAL
Intervention: Web-based skills training and motivational intervention
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control website focusing on relaxation skills
Number of subjects: 112
Study: 18538053

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% w/v
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.125% w/v
Number of subjects: 54
Study: 16103764

Group type: EXPERIMENTAL
Intervention: Didanosine (ddI) plus stavudine (d4T)
Number of subjects: 509

Group type: COMPARATOR
Intervention: Control subjects (not receiving ddI plus d4T)
Number of subjects: 509
Study: 12421773

Group type: EXPERIMENTAL
Intervention: High dose corticosteroid infusion for 48 hours after head injury
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study: 12198662

Group type: EXPERIMENTAL
Intervention: Sandostatin LAR 30 mg injection once every 4 weeks for 6 doses
Number of subjects: 70
Study: 9518395

Group type: EXPERIMENTAL
Intervention: Intensive therapy (3 or more insulin injections daily or continuous subcutaneous infusion of insulin, guided by 4 or more glucose tests per day)
Number of subjects: 855

Group type: COMPARATOR
Intervention: Conventional therapy (1 or 2 insulin injections daily)
Number of subjects: 855

Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 855
Study: 7536209

Group type: EXPERIMENTAL
Intervention: rhIGF‐I (120 micrograms/kg, sc, daily)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (6 months) followed by rhIGF‐I (6 months)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: rhIGF‐I
Number of subjects: 17
Study: 2239785

Group type: EXPERIMENTAL
Intervention: Folic acid (400 micrograms)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Thiamin (10 mg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Folic-acid-plus-thiamin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 214218

Group type: COMPARATOR
Intervention: oral 5‐Fluorouracil (5FU)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: oral 5‐Fu plus Streptozotocin
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: oral 5‐Fu plus Methyl‐CCNU
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Adriamycin
Number of subjects: 168
Study: 7043345

Group type: EXPERIMENTAL
Intervention: Ticarcillin (6 g intravenously immediately after delivery, with a second 3-g dose 6 to 8 hours after delivery for some patients)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Ticarcillin (for high-risk patients)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Placebo (for high-risk patients)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Ticarcillin (for low-risk patients)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Placebo (for low-risk patients)
Number of subjects: 259
Study: 30188912

Group type: EXPERIMENTAL
Intervention: Cardiovascular Health Awareness Program (CHAP)
Number of subjects: 39
Study: 26074306

Group type: EXPERIMENTAL
Intervention: Telephone tinnitus education
Number of subjects: 0
Study: 24626789

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy and family‐focused treatment (21 sessions over 9 months)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Pharmacotherapy and enhanced care (three weekly sessions of family psychoeducation)
Number of subjects: 145
Study: 22001312

Group type: EXPERIMENTAL
Intervention: Counseling sessions on breastfeeding and complementary feeding (5 sessions on breastfeeding and 1 session on complementary feeding)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Control group (no counseling)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Counseling sessions on breastfeeding
Number of subjects: 323
Study: 20044231

Group type: EXPERIMENTAL
Intervention: Peer counseling intervention
Number of subjects: 11
Study: 18367770

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Formoterol (24 microg)
Number of subjects: 60
Study: 15846191

Group type: EXPERIMENTAL
Intervention: Brief folic acid counseling, a reminder phone call, and 30 folic acid tablets (n = 162 women)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Counseling about other preventive health behaviors and a folic acid informational pamphlet (n = 160 women)
Number of subjects: 322
Study: 12527539

Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (PST)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Supportive therapy (ST)
Number of subjects: 25
Study: 10531630

Group type: EXPERIMENTAL
Intervention: Methadone formulation 1
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Methadone formulation 2
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Methadone formulation 3
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Methadone formulations (all)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Subjective symptoms
Number of subjects: 18
Study: 8888599

Group type: EXPERIMENTAL
Intervention: Participants urged to be honest
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants urged to be polite
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No special instructions given
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Artists personally invested in paintings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Artists not personally invested in paintings
Number of subjects: 0
Study: 1984375

Group type: EXPERIMENTAL
Intervention: 0.6% isoflurane
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 1.2% isoflurane
Number of subjects: 21

Group type: COMPARATOR
Intervention: midazolam and fentanyl
Number of subjects: 21
Study: 6366821

Group type: EXPERIMENTAL
Intervention: Zopiclone 3.75 mg
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Zopiclone 5.0 mg
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Zopiclone 10.0 mg
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 30700487

Group type: EXPERIMENTAL
Intervention: Educational condition addressing knowledge, risk communication, and enhancing self-efficacy regarding vaccination
Number of subjects: 8875

Group type: COMPARATOR
Intervention: Low-intensity information condition
Number of subjects: 8875
Study: 30318972

Group type: EXPERIMENTAL
Intervention: Rosemary water (250 mL)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Plain mineral water
Number of subjects: 80
Study: 26894621

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine‐impregnated washcloths used to wipe the patient's body once daily
Number of subjects: 481

Group type: COMPARATOR
Intervention: Non‐antimicrobial soap (control group)
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine‐impregnated washcloths
Number of subjects: 481
Study: 24463982

Group type: EXPERIMENTAL
Intervention: Mandibular Advancement Device (MAD)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo Oral Appliance (POA)
Number of subjects: 29
Study: 22766993

Group type: EXPERIMENTAL
Intervention: Medium light roast (MLR) coffee
Number of subjects: 20

Group type: COMPARATOR
Intervention: Medium roast (MR) coffee
Number of subjects: 20
Study: 20799923

Group type: EXPERIMENTAL
Intervention: Randomized clinical trials (RCTs) for depression
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Clinicaltrials.gov studies
Number of subjects: 150
Study: 17513398

Group type: EXPERIMENTAL
Intervention: Whole-grain products (3 bread slices, 2 crisp bread slices, 1 portion muesli, and 1 portion pasta)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Refined-grain products (3 bread slices, 2 crisp bread slices, 1 portion muesli, and 1 portion pasta)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Whole-grain products
Number of subjects: 30

Group type: COMPARATOR
Intervention: Refined-grain products
Number of subjects: 30
Study: 16194247

Group type: EXPERIMENTAL
Intervention: Learner-control multimedia learning environment courseware package (n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Program-control multimedia learning environment courseware package (n = 15)
Number of subjects: 30
Study: 11820660

Group type: COMPARATOR
Intervention: Conventional trabeculectomy (n = 40)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Small incision trabeculectomy (SIT) avoiding Tenon's capsule (n = 40)
Number of subjects: 80
Study: 10740301

Group type: EXPERIMENTAL
Intervention: Intravenous ethamsylate (12.5 mg/kg) six hourly for four days
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control group (no ethamsylate)
Number of subjects: 192
Study: 8753942

Group type: EXPERIMENTAL
Intervention: CS+ (angry face) from male
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CS+ (angry face) from female
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CS+ (angry face from adult male)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CS+ (happy face) from adult male
Number of subjects: 0
Study: 1928663

Group type: EXPERIMENTAL
Intervention: Cromoglycate plus chlorphenamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cromoglycate plus tetryzolin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imidazolin plus nafazolin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7039401

Group type: EXPERIMENTAL
Intervention: FPL 57787 18 mg x 4
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 28987824

Group type: EXPERIMENTAL
Intervention: Nurse-led programme for comorbidities management, cost € 16,804.2
Number of subjects: 0
Study: 27108827

Group type: EXPERIMENTAL
Intervention: McGrath MAC
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Airtraq NT
Number of subjects: 63

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 63
Study: 24664177

Group type: EXPERIMENTAL
Intervention: Unpleasant odor (Civette, smelling like feces)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Pleasant odor (Rose)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Odorless control condition
Number of subjects: 45
Study: 22405475

Group type: EXPERIMENTAL
Intervention: Lifestyle interventions (increased physical activity)
Number of subjects: 810

Group type: COMPARATOR
Intervention: Advice-only control group
Number of subjects: 810
Study: 20136418

Group type: EXPERIMENTAL
Intervention: Intravitreal injections of 2.5 mg (0.1 ml) bevacizumab
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30